This application relates generally to the field of intraocular devices.
The human eye functions to provide vision by transmitting and focusing light through a clear outer portion called the cornea, and further refining the focus of the image onto a retina by way of a crystalline lens. The quality of the focused image depends on many factors including the size and shape of the eye, and the transparency of the cornea and the lens.
The optical power of the eye is determined by the optical power of the cornea and the crystalline lens. In a normal, healthy eye, sharp images of distant objects are formed on the retina (emmetropia). In many eyes, images of distant objects are either formed in front of the retina because the eye is abnormally long or the cornea is abnormally steep (myopia), or formed in back of the retina because the eye is abnormally short or the cornea is abnormally flat (hyperopia).
Some people suffer from cataracts in which the crystalline lens undergoes a loss of transparency. In such cases, the crystalline lens can be removed and replaced with an intraocular lens (IOL). However, some intraocular lenses may leave defects in a patient's non-distance eyesight.
Intraocular lenses are often uniquely molded and then machined to include the appropriate optical properties. However, if the intraocular lens is not perfectly milled across the entire anterior and posterior surfaces of the intraocular lens, the intraocular lens can have the incorrect power and become unusable. To remove this manufacturing complexity, an intraocular lens, or implant, can be formed where only a central region of the intraocular implant has optical power. This powered portion of the implant (also referred to herein as a lens or optic) can interface or mechanically couple with a lens holder having negligible (e.g., less than 0.25 diopters) or no optical power. In this configuration, the same lens holder can interface with different powered lenses. Because the lens holder has negligible or no power, the anterior and posterior surfaces of the lens holder do not need to be perfectly milled to specification. This reduces the number of unique steps needed to create an intraocular lens and, in particular, an IOL with a small aperture to increase depth of focus.
As an example, the intraocular implant can include a lens holder and an optic. The lens holder can include an outer periphery and an inner periphery. The inner periphery of the lens holder can define an aperture extending from an anterior surface of the lens holder to a posterior surface of the lens holder. At least a portion of the lens holder can be substantially opaque to visible light. The substantially opaque portion can be disposed about the aperture. An optic can be positioned in the aperture and mechanically coupled or interlocked with the inner periphery of the lens holder. The aperture may be configured to increase depth of focus in a human patient when the intraocular implant is implanted in an eye of the human patient.
As another example, the intraocular implant can include a lens holder and a powered optic. The lens holder can include an outer periphery and an inner periphery. The inner periphery of the lens holder can define an aperture extending from an anterior surface of the lens holder to a posterior surface of the lens holder. The lens holder can have negligible or no power, or can be powered. The powered optic can be positioned in the aperture and mechanically coupled or interlocked with the lens holder. The aperture may be configured to increase depth of focus in a human patient when the intraocular implant is implanted in an eye of the human patient.
A method of manufacturing the intraocular implant can include forming a lens holder. The lens holder can include an outer periphery and an inner periphery. The inner periphery of the lens holder can include an aperture extending from an anterior surface of the lens holder to a posterior surface of the lens holder. The method can also include forming an optic. After forming the lens holder and the optic, the method can include inserting the optic into the aperture and mechanically coupling or interlocking the optic with the inner periphery of the lens holder.
Any feature, structure, or step disclosed herein can be replaced with or combined with any other feature, structure, or step disclosed herein, or omitted. Further, for purposes of summarizing the disclosure, certain aspects, advantages, and features of the inventions have been described herein. It is to be understood that not necessarily any or all such advantages are achieved in accordance with any particular embodiment of the inventions disclosed herein. No aspects of this disclosure are essential or indispensable.
Various embodiments are depicted in the accompanying drawings for illustrative purposes and should in no way be interpreted as limiting the scope of the embodiments. Furthermore, various features of different disclosed embodiments can be combined to form additional embodiments, which are part of this disclosure.
Patients who undergo intraocular lens (IOL) implantation surgery may still suffer from defects in their non-distance eyesight. One technique for treating such defects is by including a small aperture within the IOL that allows light to pass through to the retina to increase depth of focus. The light rays that pass through the mask within the IOL converge at a single focal point on the retina, while the light rays that would not converge at the single point on retina are blocked by the mask. This disclosure describes methods for manufacturing an implant, such as an IOL, having an aperture. The intraocular implant may be implanted in the anterior chamber or the posterior chamber of the eye. In the posterior chamber, the implant may be fixated in the ciliary sulcus, in the capsular bag, or anywhere an intraocular implant is fixated.
As shown in
The lens holder 102 can have an anterior surface 112 and a posterior surface 114. Each of the anterior and posterior surfaces 112, 114 can be curved or planar. For example, as shown
Although some of the embodiments described herein are discussed with respect to a lens holder 102 having negligible or no optical power, in other configurations, the lens holder 102 may have optical power, for example the same or different optical power as the optic 108.
The intraocular implant 100 can include haptics 110 for positioning the intraocular implant 100 in the eye. The haptics 110 can be separately attached to the lens holder 102 or integrally formed with and include a same material as the main body 134. The main body 134 and haptics 110 can take on any of the configurations described in U.S. Pat. No. 9,492,272, which is hereby incorporated by reference in its entirety herein.
The aperture 116 can extend from the anterior surface 112 of the main body 134 to the posterior surface 114 of the main body 134. A diameter of the aperture 116 at the anterior surface 112 and/or the posterior surface 114 can be greater than a diameter of the aperture 116 taken at a transverse midline of the aperture 116. As shown in
Alternatively, a diameter of the central region can be greater than a diameter of the anterior region and/or the posterior region of the aperture. The lens holder can include a recess that defines the increased diameter section of the aperture. The recess can be an annular recess in a central region of the aperture that receives a projection on the optic.
The lens holder 102 can include one or more materials. For example, the lens holder material can include a hydrophobic material and/or a low-viscosity material. The lens holder material can include polymers (e.g. PMMA, PVDF, polypropylene, polycarbonate, PEEK, polyethylene, acrylic, acrylic copolymers, polystyrene, PVC, polysulfone, silicone) or hydrogels. The main body 134 of the lens holder 102 can be substantially transparent to visible light. In some embodiments, the main body 134 of the lens holder 102 can be substantially opaque to visible light and substantially transparent to near infrared (IR) light. Further near-IR details are disclosed in U.S. Pat. No. 9,545,303, which is hereby incorporated by reference in its entirety herein.
The lens holder material can include an ultraviolet light absorber to protect the eye from ultraviolet light. The lens holder material can also include a light-sensitive initiator to allow the lens holder material to be photo-cured by exposure to light. The light-sensitive initiator can include various biocompatible initiators, including, but not limited to, acylphosphine oxide initiators, such as Irgacure® 819.
At least a portion of the main body 134 adjacent to and surrounding the aperture 116 can include opacity to prevent substantially all or all visible light from being transmitted through the portion of the main body 134. For example, the portion having opacity can prevent transmission of at least about 92 percent, at least about 95 percent, or at least about 99 percent of all incident, visible light.
At least a partial or entire thickness of the main body 134 can include the opacity. For example, the lens holder 102 can include a mask 104 that is substantially or completely opaque to visible light. The mask 104 can be positioned on a posterior or anterior surface of the main body 134 or embedded within the main body 134. For example, the mask 104 can be centrally embedded in the main body 134. As shown in
The mask 104 can be symmetrical about a central axis. For example the mask 104 can be circular. The mask 104 can have an outer diameter of at least about 3 mm and/or less than about 6 mm, such as at least about 3 mm and/or less than or equal to about 4 mm, for example about 3.2 mm. An inner diameter of the mask 104 can be any size that is effective to increase the depth of focus of an eye of a patient. The mask 104 can include an aperture with a diameter of at least about 0.85 mm and/or less than or equal to about 2.2 mm, at least about 1.1 mm and/or less than or equal to about 2.0 mm, or at least about 1.4 mm and/or less than or equal to about 1.8 mm. In other configurations, the inner diameter of the mask 104 may be sized for any suitable optic.
A thickness of the mask 104 can be within a range from greater than zero to about 0.6 mm, about 1 micron to about 40 microns, about 5 microns to about 20 microns, about 5 microns to about 15 microns, or otherwise. For example, the thickness of the mask 104 can be about 15 microns, about 10 microns, about 8 microns, about 5 microns, or otherwise.
The mask material can be naturally opaque or treated with a dye or other pigmentation agent to render the mask 104 substantially or completely opaque. The mask material can be the same material or a different material than the lens holder material. For example, the mask material can include a polymeric material (e.g. PMMA, PVDF, polypropylene, polycarbonate, PEEK, polyethylene, acrylic, acrylic copolymers, polystyrene, PVC, polysulfone), hydrogels, or fibrous materials.
As another example, the mask can include a photochromic material. When implanted, the photochromic material can temporarily or permanently darken to enhance near vision. Further photochromic material details are disclosed in U.S. Pat. Nos. 9,204,962 and 9,545,303, which are hereby incorporated by reference in their entireties herein.
As another example, the mask can block the transmission of substantially all visible light while remaining transparent to the near IR light used in ocular imaging. The mask can permit the transmission of electromagnetic radiation with a wavelength between about 750 nm and about 1500 nm through mask 104. The mask 104 can be dyed or otherwise treated to provide these transmissivity properties. Further near-IR details are disclosed in U.S. Pat. No. 9,545,303, which is hereby incorporated by reference in its entirety herein.
The mask 104 can be molded, printed, formed, etched, laser-created, heat- or light-created, or otherwise created in or attached to the main body 134. For example, the main body 134 can be cast molded around the mask 104. During the molding process, the mask 104 can be centered on a protruding pin in the mold. When the main body 134 is removed from the mold, the protruding pin leaves behind a void that is the aperture 116. The mold can be shaped to form an interfacing structure in the inner periphery 130 of the lens holder 102, or after molding, the lens holder 102 can be machined to form the interfacing structure in the inner periphery 130 of the lens holder 102. Formation of the lens holder 102 and centration of the mask 104 can also be performed using any of the techniques described in U.S. Pat. Nos. 9,492,272 and 9,427,922, which are hereby incorporated by reference in their entireties herein.
The optic 108 can include an anterior region 122, a central region 120, and a posterior region 124. A diameter of the anterior region 122 and the posterior region 124 can be greater than a diameter of the central region 120. For example, the central region 120 can include an annular recess configured to interface with and mechanically interlock with the protrusion 118 on the inner periphery 130 of the lens holder 102. A thickness of the central region 120 can be the same or different than a thickness of the anterior region 122 and/or the posterior region 124. For example, the thickness of the central region 120 can be greater than the thickness of the anterior region 122 and the posterior region 124. Alternatively, the outer profile of the optic 108 can be inverted such that a diameter of the central region 120 is greater than a diameter of the anterior region 122 and the posterior region 124.
As shown in
The optic 108 can include a same or different material than the main body 134 and/or the mask 134. The optic material can include a hydrophobic material and/or a low-viscosity material. The optic material can include polymers (e.g. PMMA, PVDF, polypropylene, polycarbonate, PEEK, polyethylene, acrylic, acrylic copolymers, polystyrene, PVC, polysulfone, silicone) or hydrogels.
The optic 108 and/or the lens holder 102 may include indicia, for example on an anterior surface thereof, to assist in placement of the optic 108 in the lens holder 102 and/or in the eye. For example, the indicia can be configured to align the optic 108 with particular ocular anatomy.
The main body 134 can be more flexible than the optic 108 to facilitate insertion of the optic 108 into the main body 134. In this configuration, the aperture 116 flexes to permit insertion of the optic 108. As an example, the main body 108 can include PMMA and the main body 134 can include hydrophobic acrylic.
As described above, the optic 108 is coupled to the lens holder 102. Rather than being integrally molded or formed, the optic 108 can be separately formed and mechanically coupled the lens holder 102. For example, the optic 108 and the lens holder 102 can be mechanically interlocked by a press-fit, snap-fit, threaded interface, or otherwise.
As shown in
Alternatively, the optic 108 can include an annular rib projecting from a central region of the optic 108, and the lens holder 102 can include a recess in a central region of the inner periphery 130 of the lens holder 102. Although
When coupled together, the anterior region 136, central region 138, and posterior region 140 of the aperture 116 can receive the corresponding anterior region 122, central region 120, and posterior region 124 of the optic 108. A posterior edge of the anterior region 122 of the optic 108 can abut an anterior edge of the central region 138 of the aperture 116. An anterior edge of the posterior region 128 of the optic 108 can abut a posterior edge of the central region 138 of the aperture.
With reference to
Similar to the intraocular implant 100 shown in
The entire main body 234, from an anterior surface 212 of the main body 234 to a posterior surface 214 of the main body 234, includes opacity to prevent substantially all or all visible light from being transmitted through the any portion of the main body 234. For example, the main body 234 can prevent transmission of at least about 92 percent, at least about 95 percent, or at least about 99 percent of all incident, visible light.
The entire main body 234 can be constructed from the same material(s). The main body material can be naturally opaque or treated with a dye or other pigmentation agent to render the main body 234 substantially or completely opaque. The main body material can include a polymeric material (e.g. PMMA, PVDF, polypropylene, polycarbonate, PEEK, polyethylene, acrylic, acrylic copolymers, polystyrene, PVC, polysulfone), hydrogels, or fibrous materials.
As another example, the main body material can include a photochromic material. When implanted, the photochromic material can temporarily or permanently darken to enhance near vision. Further photochromic material details are disclosed in U.S. Pat. Nos. 9,204,962 and 9,545,303, which are hereby incorporated by reference in their entireties herein.
As another example, the main body 234 can block the transmission of substantially all visible light while remaining transparent to the near IR light used in ocular imaging. For example, the main body 234 can permit the transmission of electromagnetic radiation with a wavelength between about 750 nm and about 1500 nm through mask 104. The main body 234 be dyed or otherwise treated to achieve these transmissivity properties. Further near IR details are disclosed in U.S. Pat. No. 9,545,303, which is hereby incorporated by reference in its entirety herein.
The intraocular implant 200 can include haptics 210 for positioning the intraocular implant 200 in the eye. The haptics 210 can be separately attached to the lens holder 202 or integrally formed with and include the same material(s) as the lens holder 202. For example, the haptics 210 can include the same opacity as the main body 234.
Terminology
Although certain intraocular implants have been described herein in connection with specific optics or lenses, the optic may be any suitable optic for an intraocular lens, including but not limited to, a spherical lens, a monofocal lens, a multifocal lens, an aspheric lens, a photochromic lens, or a toric lens.
Conditional language, such as “can,” “could,” “might,” or “may,” unless specifically stated otherwise, or otherwise understood within the context as used, is generally intended to convey that certain embodiments include, while other embodiments do not include, certain features, elements, and/or steps. Thus, such conditional language is not generally intended to imply that features, elements, and/or steps are in any way required for one or more embodiments or that one or more embodiments necessarily include logic for deciding, with or without user input or prompting, whether these features, elements, and/or steps are included or are to be performed in any particular embodiment.
The terms “comprising,” “including,” “having,” and the like are synonymous and are used inclusively, in an open-ended fashion, and do not exclude additional elements, features, acts, operations, and so forth. Also, the term “or” is used in its inclusive sense (and not in its exclusive sense) so that when used, for example, to connect a list of elements, the term “or” means one, some, or all of the elements in the list.
The terms “approximately,” “about,” and “substantially” as used herein represent an amount close to the stated amount that still performs a desired function or achieves a desired result. For example, unless otherwise defined herein, the terms “approximately,” “about,” and “substantially” may refer to an amount that is within less than 10% of the stated amount, as the context may dictate.
The ranges disclosed herein also encompass any and all overlap, sub-ranges, and combinations thereof. Language such as “up to,” “at least,” “greater than,” “less than,” “between” and the like includes the number recited. Numbers preceded by a term such as “about” or “approximately” include the recited numbers. For example, “about 3 mm” includes “3 mm.”
Although certain embodiments and examples have been described herein, it will be understood by those skilled in the art that many aspects of the methods and IOLs shown and described in the present disclosure may be differently combined and/or modified to form still further embodiments or acceptable examples. All such modifications and variations are intended to be included herein within the scope of this disclosure. A wide variety of designs and approaches are possible. No feature, structure, or step disclosed herein is essential or indispensable.
For purposes of this disclosure, certain aspects, advantages, and novel features are described herein. It is to be understood that not necessarily all such advantages may be achieved in accordance with any particular embodiment. Thus, for example, those skilled in the art will recognize that the disclosure may be embodied or carried out in a manner that achieves one advantage or a group of advantages as taught herein without necessarily achieving other advantages as may be taught or suggested herein.
Moreover, while illustrative embodiments have been described herein, the scope of any and all embodiments having equivalent elements, modifications, omissions, combinations (e.g., of aspects across various embodiments), adaptations and/or alterations as would be appreciated by those skilled in the art based on the present disclosure. The limitations in the claims are to be interpreted broadly based on the language employed in the claims and not limited to the examples described in the present specification or during the prosecution of the application, which examples are to be construed as non-exclusive. Further, the actions of the disclosed processes and methods may be modified in any manner, including by reordering actions and/or inserting additional actions and/or deleting actions. It is intended, therefore, that the specification and examples be considered as illustrative only, with a true scope and spirit being indicated by the claims and their full scope of equivalents.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2019/031189 | 5/7/2019 | WO | 00 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2019/217471 | 11/14/2019 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
2350421 | Schoder et al. | Jun 1944 | A |
2470927 | Hale, Jr. | May 1949 | A |
3034403 | Neefe | May 1962 | A |
3270099 | Camp | Aug 1966 | A |
3458870 | Stone | Aug 1969 | A |
3578850 | Grant | May 1971 | A |
3776230 | Neefe | Dec 1973 | A |
3794414 | Wesley | Feb 1974 | A |
3877502 | Hunckler | Apr 1975 | A |
3996627 | Deeg et al. | Dec 1976 | A |
4010496 | Neefe | Mar 1977 | A |
4104338 | Guerrieri | Aug 1978 | A |
4116439 | Chavarria et al. | Sep 1978 | A |
4210391 | Cohen | Jul 1980 | A |
4298996 | Barnet | Nov 1981 | A |
4340283 | Cohen | Jul 1982 | A |
4402396 | Graham | Sep 1983 | A |
4402579 | Poler | Sep 1983 | A |
4423728 | Lieberman | Jan 1984 | A |
4435050 | Poler | Mar 1984 | A |
4450593 | Poler | May 1984 | A |
4470159 | Peyman | Sep 1984 | A |
4505855 | Bruns et al. | Mar 1985 | A |
4512039 | Lieberman | Apr 1985 | A |
4563565 | Kampfer et al. | Jan 1986 | A |
4575373 | Johnson | Mar 1986 | A |
4596578 | Kelman | Jun 1986 | A |
4607617 | Choyce | Aug 1986 | A |
4624669 | Grendahl | Nov 1986 | A |
4639105 | Neefe | Jan 1987 | A |
4646720 | Peyman et al. | Mar 1987 | A |
4655774 | Choyce | Apr 1987 | A |
4665913 | Esperance, Jr. | May 1987 | A |
4669466 | L'Esperance | Jun 1987 | A |
4669834 | Richter | Jun 1987 | A |
4676790 | Kern | Jun 1987 | A |
4676791 | LeMaster et al. | Jun 1987 | A |
4678422 | York | Jul 1987 | A |
4701038 | Neefe | Oct 1987 | A |
4715858 | Lindstrom | Dec 1987 | A |
4744647 | Meshel et al. | May 1988 | A |
4767647 | Bree | Aug 1988 | A |
4795462 | Grendahl | Jan 1989 | A |
4798608 | Grendahl | Jan 1989 | A |
4799784 | Safir | Jan 1989 | A |
4799931 | Lindstrom | Jan 1989 | A |
4807623 | Lieberman | Feb 1989 | A |
4813955 | Achatz et al. | Mar 1989 | A |
4815690 | Shepherd | Mar 1989 | A |
4817789 | Paul | Apr 1989 | A |
4830855 | Stewart | May 1989 | A |
4842599 | Bronstein | Jun 1989 | A |
4842782 | Portney | Jun 1989 | A |
4851003 | Lindstrom | Jul 1989 | A |
4863466 | Schlegel | Sep 1989 | A |
4881860 | Kanazawa | Nov 1989 | A |
4903695 | Warner et al. | Feb 1990 | A |
4907586 | Bille et al. | Mar 1990 | A |
4928815 | Paul | May 1990 | A |
4955904 | Atebara et al. | Sep 1990 | A |
4976732 | Vorosmarthy | Dec 1990 | A |
4994080 | Shepard | Feb 1991 | A |
5013319 | Davis | May 1991 | A |
5030230 | White | Jul 1991 | A |
5034166 | Rawlings et al. | Jul 1991 | A |
5041133 | Sayano et al. | Aug 1991 | A |
5055602 | Melpolder | Oct 1991 | A |
5087015 | Galley | Feb 1992 | A |
5090955 | Simon | Feb 1992 | A |
5092880 | Ohmi | Mar 1992 | A |
5094521 | Jolson et al. | Mar 1992 | A |
5098443 | Parel et al. | Mar 1992 | A |
5108427 | Majercik et al. | Apr 1992 | A |
5112328 | Taboada et al. | May 1992 | A |
5120120 | Cohen | Jun 1992 | A |
5120121 | Rawlings et al. | Jun 1992 | A |
5137441 | Fogarty | Aug 1992 | A |
5147395 | Willis | Sep 1992 | A |
5171318 | Gibson et al. | Dec 1992 | A |
5185107 | Blake | Feb 1993 | A |
5188494 | Hatin | Feb 1993 | A |
5192316 | Ting | Mar 1993 | A |
5196026 | Barrett et al. | Mar 1993 | A |
5213749 | Huss et al. | May 1993 | A |
5260727 | Oksman et al. | Nov 1993 | A |
5266241 | Parekh | Nov 1993 | A |
5269795 | Arnott | Dec 1993 | A |
5269812 | White | Dec 1993 | A |
5274404 | Michael | Dec 1993 | A |
5288436 | Liu et al. | Feb 1994 | A |
5290892 | Namdaran et al. | Mar 1994 | A |
5292514 | Capecchi et al. | Mar 1994 | A |
5300116 | Chirila et al. | Apr 1994 | A |
5312330 | Klopotek | May 1994 | A |
5314439 | Sugita | May 1994 | A |
5314961 | Anton et al. | May 1994 | A |
5332802 | Kelman et al. | Jul 1994 | A |
5336261 | Barrett et al. | Aug 1994 | A |
5354331 | Schachar et al. | Oct 1994 | A |
5358520 | Patel | Oct 1994 | A |
5372580 | Simon et al. | Dec 1994 | A |
5391201 | Barrett et al. | Feb 1995 | A |
5441511 | Hanna | Aug 1995 | A |
5474548 | Knopp et al. | Dec 1995 | A |
5507740 | O'Donnell, Jr. | Apr 1996 | A |
5507806 | Blake | Apr 1996 | A |
5547468 | Simon et al. | Apr 1996 | A |
D375245 | Irving | Nov 1996 | S |
5578080 | McDonald | Nov 1996 | A |
5603774 | LeBoeuf et al. | Feb 1997 | A |
5607437 | Simon et al. | Mar 1997 | A |
5624456 | Hellenkamp | Apr 1997 | A |
5627613 | Kaneko | May 1997 | A |
5628794 | Lindstrom | May 1997 | A |
5628795 | Langerman | May 1997 | A |
5647865 | Swinger | Jul 1997 | A |
5652638 | Roffman et al. | Jul 1997 | A |
5653752 | Silvestrini et al. | Aug 1997 | A |
5662706 | Legerton et al. | Sep 1997 | A |
5674284 | Chang et al. | Oct 1997 | A |
5693268 | Widman et al. | Dec 1997 | A |
5697923 | Poler | Dec 1997 | A |
5702440 | Portney | Dec 1997 | A |
5708049 | Katagiri et al. | Jan 1998 | A |
5713957 | Steele et al. | Feb 1998 | A |
5722971 | Peyman | Mar 1998 | A |
5725575 | O'Donnell, Jr. | Mar 1998 | A |
5728156 | Gupta et al. | Mar 1998 | A |
5746558 | Nygren et al. | May 1998 | A |
5752967 | Kritzinger et al. | May 1998 | A |
5757458 | Miller et al. | May 1998 | A |
5769889 | Kelman | Jun 1998 | A |
5774202 | Abraham et al. | Jun 1998 | A |
5786883 | Miller et al. | Jul 1998 | A |
5824086 | Silvestrini | Oct 1998 | A |
5837156 | Cumming | Nov 1998 | A |
5843105 | Mathis et al. | Dec 1998 | A |
5864128 | Plesko | Jan 1999 | A |
5870167 | Knopp et al. | Feb 1999 | A |
5876442 | Lipshitz et al. | Mar 1999 | A |
5895610 | Chang et al. | Apr 1999 | A |
5905561 | Lee et al. | May 1999 | A |
5910537 | Feingold et al. | Jun 1999 | A |
5913898 | Feingold et al. | Jun 1999 | A |
5919185 | Peyman | Jul 1999 | A |
5925294 | Shibuya | Jul 1999 | A |
5964748 | Peyman | Oct 1999 | A |
5964776 | Peyman | Oct 1999 | A |
5965330 | Evans et al. | Oct 1999 | A |
5980040 | Xu et al. | Nov 1999 | A |
6007579 | Lipshitz | Dec 1999 | A |
6017121 | Chateau et al. | Jan 2000 | A |
6063073 | Peyman | May 2000 | A |
6090141 | Lindstrom | Jul 2000 | A |
6102946 | Nigam | Aug 2000 | A |
6106553 | Feingold et al. | Aug 2000 | A |
6110166 | Juhasz et al. | Aug 2000 | A |
6138307 | McDonald | Oct 2000 | A |
6152959 | Portney | Nov 2000 | A |
6164777 | Li et al. | Dec 2000 | A |
6171336 | Sawusch | Jan 2001 | B1 |
6178593 | Carlson | Jan 2001 | B1 |
6197019 | Peyman | Mar 2001 | B1 |
6201036 | Fedorov et al. | Mar 2001 | B1 |
6203538 | Peyman | Mar 2001 | B1 |
6210401 | Lai | Apr 2001 | B1 |
6217571 | Peyman | Apr 2001 | B1 |
6217596 | Farah | Apr 2001 | B1 |
6221067 | Peyman | Apr 2001 | B1 |
6228113 | Kaufman | May 2001 | B1 |
6228114 | Lee | May 2001 | B1 |
6228115 | Hoffmann et al. | May 2001 | B1 |
6264648 | Peyman | Jul 2001 | B1 |
6277146 | Peyman | Aug 2001 | B1 |
6280470 | Peyman | Aug 2001 | B1 |
6280471 | Peyman et al. | Aug 2001 | B1 |
6302877 | Ruiz | Oct 2001 | B1 |
6304390 | Takanashi | Oct 2001 | B1 |
6308590 | Berto | Oct 2001 | B1 |
6335190 | Zhou et al. | Jan 2002 | B1 |
6361560 | Nigam | Mar 2002 | B1 |
6376153 | Uchikawa et al. | Apr 2002 | B2 |
6387379 | Goldberg et al. | May 2002 | B1 |
6391230 | Sarbadhikari | May 2002 | B1 |
6416179 | Lieberman et al. | Jul 2002 | B1 |
6423093 | Hicks et al. | Jul 2002 | B1 |
6432246 | Blake | Aug 2002 | B1 |
6436092 | Peyman | Aug 2002 | B1 |
6458141 | Peyman | Oct 2002 | B1 |
6461384 | Hoffmann et al. | Oct 2002 | B1 |
6469844 | Iwase et al. | Oct 2002 | B1 |
6480346 | Funakoshi | Nov 2002 | B2 |
6491637 | Foster et al. | Dec 2002 | B2 |
6497700 | LaHaye | Dec 2002 | B1 |
6515006 | Horn | Feb 2003 | B2 |
6533416 | Fermigier et al. | Mar 2003 | B1 |
6551307 | Peyman | Apr 2003 | B2 |
6554424 | Miller et al. | Apr 2003 | B1 |
6554860 | Hoffmann et al. | Apr 2003 | B2 |
6555103 | Leukel et al. | Apr 2003 | B2 |
6575573 | Lai et al. | Jun 2003 | B2 |
6581993 | Nigam | Jun 2003 | B2 |
6588902 | Isogai | Jul 2003 | B2 |
6589280 | Koziol | Jul 2003 | B1 |
6607527 | Ruiz et al. | Aug 2003 | B1 |
6613088 | Babizhayev | Sep 2003 | B1 |
6638304 | Azar | Oct 2003 | B2 |
6649722 | Rosenzweig et al. | Nov 2003 | B2 |
6655804 | Streibig | Dec 2003 | B2 |
6692126 | Xie et al. | Feb 2004 | B1 |
6702807 | Peyman | Mar 2004 | B2 |
6726322 | Andino et al. | Apr 2004 | B2 |
6740116 | Morcher | May 2004 | B2 |
6755858 | White | Jun 2004 | B1 |
6786926 | Peyman | Sep 2004 | B2 |
6811256 | Becherer et al. | Nov 2004 | B1 |
6855163 | Peyman | Feb 2005 | B2 |
6874886 | Miller et al. | Apr 2005 | B2 |
6899424 | Miller et al. | May 2005 | B2 |
6949093 | Peyman | Sep 2005 | B1 |
6951556 | Epstein | Oct 2005 | B2 |
6966648 | Miller et al. | Nov 2005 | B2 |
6989008 | Peyman | Jan 2006 | B2 |
6997428 | Andino et al. | Feb 2006 | B1 |
7001374 | Peyman | Feb 2006 | B2 |
7008447 | Koziol | Mar 2006 | B2 |
7025455 | Roffman | Apr 2006 | B2 |
7061693 | Zalevsky | Jun 2006 | B2 |
7099057 | Parker et al. | Aug 2006 | B2 |
7276080 | Murakami et al. | Oct 2007 | B2 |
7287852 | Fiala | Oct 2007 | B2 |
7364674 | Hoover | Apr 2008 | B1 |
7399811 | Mentak et al. | Jul 2008 | B2 |
7404637 | Miller et al. | Jul 2008 | B2 |
7404638 | Miller et al. | Jul 2008 | B2 |
7446157 | Mentak et al. | Nov 2008 | B2 |
7455404 | Bandhauer et al. | Nov 2008 | B2 |
7455691 | Feingold et al. | Nov 2008 | B2 |
7462193 | Nagamoto | Dec 2008 | B2 |
7477452 | Tsuruma | Jan 2009 | B2 |
7491350 | Silvestrini | Jan 2009 | B2 |
7497866 | Perez | Mar 2009 | B2 |
7628810 | Christie et al. | Dec 2009 | B2 |
7632431 | Ghazizadeh et al. | Dec 2009 | B2 |
7641337 | Altmann | Jan 2010 | B2 |
7645299 | Koziol | Jan 2010 | B2 |
7745555 | Mentak et al. | Jun 2010 | B2 |
7780290 | Zhao | Aug 2010 | B2 |
7842367 | Mentak | Nov 2010 | B2 |
7976577 | Silvestrini | Jul 2011 | B2 |
D645337 | Hsu et al. | Sep 2011 | S |
8043371 | Paul et al. | Oct 2011 | B2 |
8048972 | Mentak et al. | Nov 2011 | B2 |
8079706 | Silvestrini et al. | Dec 2011 | B2 |
D656526 | Christie et al. | Mar 2012 | S |
8157374 | Bandhauer et al. | Apr 2012 | B2 |
8241354 | Hong et al. | Aug 2012 | B2 |
8287592 | Silvestrini | Oct 2012 | B2 |
8343215 | Miller et al. | Jan 2013 | B2 |
D681086 | Christie et al. | Apr 2013 | S |
8420753 | Mentak et al. | Apr 2013 | B2 |
8439498 | Zhao et al. | May 2013 | B2 |
8460374 | Christie et al. | Jun 2013 | B2 |
8562131 | Zhao | Oct 2013 | B2 |
8604098 | Boydston et al. | Dec 2013 | B2 |
8740978 | Weeber et al. | Jun 2014 | B2 |
8747466 | Weeber et al. | Jun 2014 | B2 |
8752958 | Miller et al. | Jun 2014 | B2 |
8633292 | Hu et al. | Jul 2014 | B2 |
8814934 | Geraghty | Aug 2014 | B2 |
8858624 | Christie et al. | Oct 2014 | B2 |
8864824 | Silvestrini et al. | Oct 2014 | B2 |
8955968 | Zalevsky et al. | Feb 2015 | B2 |
9005281 | Christie | Apr 2015 | B2 |
9138142 | Christie et al. | Sep 2015 | B2 |
9204962 | Silvestrini | Dec 2015 | B2 |
9358103 | Wortz et al. | Jun 2016 | B1 |
9427311 | Christie et al. | Aug 2016 | B2 |
9427922 | Reboul et al. | Aug 2016 | B2 |
9492272 | Christie et al. | Nov 2016 | B2 |
9545303 | Vilupuru et al. | Jan 2017 | B2 |
9573328 | Reboul et al. | Feb 2017 | B2 |
9603704 | Silvestrini | Mar 2017 | B2 |
9744077 | Zicker et al. | Aug 2017 | B2 |
9757227 | Kushlin et al. | Sep 2017 | B2 |
9844919 | Reboul et al. | Dec 2017 | B2 |
9848979 | Vilupuru et al. | Dec 2017 | B2 |
9943403 | Webb et al. | Apr 2018 | B2 |
9987127 | Bogaert et al. | Jun 2018 | B2 |
10004593 | Webb et al. | Jun 2018 | B2 |
10183453 | Reboul et al. | Jan 2019 | B2 |
10342656 | Vilupuru et al. | Jul 2019 | B2 |
10350058 | Silvestrini | Jul 2019 | B2 |
10426600 | Coleman et al. | Oct 2019 | B2 |
10449036 | Christie et al. | Oct 2019 | B2 |
10548717 | Webb et al. | Feb 2020 | B2 |
10583619 | Reboul et al. | Mar 2020 | B2 |
10687935 | Webb et al. | Jun 2020 | B2 |
10765508 | Vilupuru et al. | Sep 2020 | B2 |
10869752 | Christie et al. | Dec 2020 | B2 |
10932902 | Reedy et al. | Mar 2021 | B2 |
10939995 | Silvestrini | Mar 2021 | B2 |
20010027314 | Peyman | Oct 2001 | A1 |
20010034516 | Peyman | Oct 2001 | A1 |
20010050750 | Breger | Dec 2001 | A1 |
20020010510 | Silverstrini | Jan 2002 | A1 |
20020082288 | Horn | Jun 2002 | A1 |
20020120329 | Lang et al. | Aug 2002 | A1 |
20020128710 | Eggleston | Sep 2002 | A1 |
20020167640 | Francis et al. | Nov 2002 | A1 |
20020196409 | Jani | Dec 2002 | A1 |
20030014042 | Juhasz et al. | Jan 2003 | A1 |
20030060880 | Feingold | Mar 2003 | A1 |
20030105521 | Perez | Jun 2003 | A1 |
20030135272 | Brady et al. | Jul 2003 | A1 |
20030149480 | Shadduck | Aug 2003 | A1 |
20030204258 | Graham et al. | Oct 2003 | A1 |
20030216763 | Patel | Nov 2003 | A1 |
20040019379 | Glick et al. | Jan 2004 | A1 |
20040056371 | Liao et al. | Mar 2004 | A1 |
20040068317 | Knight | Apr 2004 | A1 |
20040106929 | Masket | Jun 2004 | A1 |
20040140578 | Kelly et al. | Jul 2004 | A1 |
20050027355 | Murakami et al. | Feb 2005 | A1 |
20050046794 | Silvestrini et al. | Mar 2005 | A1 |
20050056954 | Devlin | Mar 2005 | A1 |
20050090895 | Peyman | Apr 2005 | A1 |
20050124983 | Frey et al. | Jun 2005 | A1 |
20050134793 | Roffman | Jun 2005 | A1 |
20050137703 | Chen | Jun 2005 | A1 |
20050143751 | Makker et al. | Jun 2005 | A1 |
20050143813 | Hovey et al. | Jun 2005 | A1 |
20050182488 | Peyman | Aug 2005 | A1 |
20050182489 | Peyman | Aug 2005 | A1 |
20050187621 | Brady | Aug 2005 | A1 |
20050288784 | Peyman | Dec 2005 | A1 |
20060064077 | Peyman | Mar 2006 | A1 |
20060079959 | Christie et al. | Apr 2006 | A1 |
20060113054 | Silvestrini | Jun 2006 | A1 |
20060135477 | Haitjema et al. | Jun 2006 | A1 |
20060184243 | Yilmaz | Aug 2006 | A1 |
20060232665 | Schowengerdt et al. | Oct 2006 | A1 |
20060235428 | Silvestrini | Oct 2006 | A1 |
20060235514 | Silvestrini | Oct 2006 | A1 |
20060241751 | Marmo et al. | Oct 2006 | A1 |
20060247659 | Moeller et al. | Nov 2006 | A1 |
20060265058 | Silvestrini | Nov 2006 | A1 |
20060268226 | Christie et al. | Nov 2006 | A1 |
20060268227 | Christie et al. | Nov 2006 | A1 |
20060268228 | Christie et al. | Nov 2006 | A1 |
20060268229 | Silvestrini et al. | Nov 2006 | A1 |
20060270946 | Silvestrini et al. | Nov 2006 | A1 |
20060271026 | Silvestrini et al. | Nov 2006 | A1 |
20060271178 | Christie et al. | Nov 2006 | A1 |
20060271179 | Christie et al. | Nov 2006 | A1 |
20060271180 | Christie et al. | Nov 2006 | A1 |
20060271181 | Christie et al. | Nov 2006 | A1 |
20060271182 | Christie et al. | Nov 2006 | A1 |
20060271183 | Christie et al. | Nov 2006 | A1 |
20060271184 | Silvestrini | Nov 2006 | A1 |
20060271185 | Silvestrini | Nov 2006 | A1 |
20060274264 | Christie et al. | Dec 2006 | A1 |
20060274265 | Christie et al. | Dec 2006 | A1 |
20070021832 | Nordan | Jan 2007 | A1 |
20070032866 | Portney | Feb 2007 | A1 |
20070091472 | Alkemper et al. | Apr 2007 | A1 |
20070092592 | Chiang | Apr 2007 | A1 |
20070129797 | Lang et al. | Jun 2007 | A1 |
20070225691 | Silvestrini et al. | Sep 2007 | A1 |
20080033546 | Liang | Feb 2008 | A1 |
20080077238 | Deacon et al. | Mar 2008 | A1 |
20080100921 | Nishikawa | May 2008 | A1 |
20080151183 | Altmann | Jun 2008 | A1 |
20080208335 | Blum et al. | Aug 2008 | A1 |
20080212030 | Bentley et al. | Sep 2008 | A1 |
20080220214 | Uozu et al. | Sep 2008 | A1 |
20080221674 | Blum et al. | Sep 2008 | A1 |
20080221676 | Coleman | Sep 2008 | A1 |
20080255663 | Akpek et al. | Oct 2008 | A1 |
20080269884 | Vannoy | Oct 2008 | A1 |
20080288066 | Cumming | Nov 2008 | A1 |
20080306587 | Your | Dec 2008 | A1 |
20090012505 | Chernyak | Jan 2009 | A1 |
20090021692 | Miller et al. | Jan 2009 | A1 |
20090287306 | Smith et al. | Jan 2009 | A1 |
20090036880 | Bischoff et al. | Feb 2009 | A1 |
20090048608 | Boukhny et al. | Feb 2009 | A1 |
20090059168 | Miller et al. | Mar 2009 | A1 |
20090069817 | Peyman | Mar 2009 | A1 |
20090164008 | Hong et al. | Jun 2009 | A1 |
20090171458 | Kellan et al. | Jul 2009 | A1 |
20090187242 | Weeber et al. | Jul 2009 | A1 |
20090204207 | Blum et al. | Aug 2009 | A1 |
20090213326 | Zhao | Aug 2009 | A1 |
20090222086 | Lui et al. | Sep 2009 | A1 |
20090234448 | Weeber et al. | Sep 2009 | A1 |
20090279048 | Hong et al. | Nov 2009 | A1 |
20090306773 | Silvestrini et al. | Dec 2009 | A1 |
20090323020 | Zhao et al. | Dec 2009 | A1 |
20100016961 | Hong et al. | Jan 2010 | A1 |
20100016965 | Hong et al. | Jan 2010 | A1 |
20100082017 | Zickler et al. | Apr 2010 | A1 |
20100082100 | Mikawa | Apr 2010 | A1 |
20100127412 | Lake | May 2010 | A1 |
20100149618 | Sprague | Jun 2010 | A1 |
20100208199 | Levis et al. | Aug 2010 | A1 |
20100225014 | Bille | Sep 2010 | A1 |
20100312336 | Hong et al. | Dec 2010 | A1 |
20110029074 | Reisin | Feb 2011 | A1 |
20110037184 | Shoji et al. | Feb 2011 | A1 |
20110051080 | Bandhauer et al. | Mar 2011 | A1 |
20110125261 | Portney | May 2011 | A1 |
20110140333 | Schaper et al. | Jun 2011 | A1 |
20110166652 | Bogaert et al. | Jul 2011 | A1 |
20110172675 | Danta et al. | Jul 2011 | A1 |
20110245919 | Pettit | Oct 2011 | A1 |
20110251685 | Chu | Oct 2011 | A1 |
20110292340 | Shimizu et al. | Dec 2011 | A1 |
20120203239 | Vukich et al. | Aug 2012 | A1 |
20120245683 | Christie et al. | Sep 2012 | A1 |
20120309761 | Chow et al. | Dec 2012 | A1 |
20120310338 | Christie et al. | Dec 2012 | A1 |
20130053953 | Silvestrini | Feb 2013 | A1 |
20130131795 | Miller et al. | May 2013 | A1 |
20130147072 | Bothe et al. | Jun 2013 | A1 |
20130190868 | Kahook | Jul 2013 | A1 |
20130238091 | Danta et al. | Sep 2013 | A1 |
20130289543 | Mordaunt | Oct 2013 | A1 |
20130324983 | Liang | Dec 2013 | A1 |
20140121767 | Simpson | May 2014 | A1 |
20140131905 | Webb | May 2014 | A1 |
20140200666 | Phillips | Jul 2014 | A1 |
20140277437 | Currie | Sep 2014 | A1 |
20140336625 | Fernandez | Nov 2014 | A1 |
20140343541 | Scott et al. | Nov 2014 | A1 |
20140379078 | Trindade | Dec 2014 | A1 |
20150025627 | Christie et al. | Jan 2015 | A1 |
20150046094 | Chaudhary et al. | Feb 2015 | A1 |
20150073549 | Webb et al. | Mar 2015 | A1 |
20150177422 | Liu et al. | Jun 2015 | A1 |
20150183173 | Linhardt et al. | Jul 2015 | A1 |
20150250583 | Rosen et al. | Sep 2015 | A1 |
20150366658 | Christie et al. | Dec 2015 | A1 |
20160100938 | Bogaert et al. | Apr 2016 | A1 |
20160297107 | Shim et al. | Oct 2016 | A1 |
20170049560 | Cherne | Feb 2017 | A1 |
20170143477 | Christie et al. | May 2017 | A1 |
20170156850 | Silvestrini et al. | Jun 2017 | A1 |
20180296322 | Webb et al. | Oct 2018 | A1 |
20180338826 | Link et al. | Nov 2018 | A1 |
20190076241 | Alarcon Heredia et al. | Mar 2019 | A1 |
20190193350 | Gu et al. | Jun 2019 | A1 |
20190269499 | Ellis | Sep 2019 | A1 |
20200000576 | Christie et al. | Jan 2020 | A1 |
20200008932 | Silvestrini | Jan 2020 | A1 |
20200179105 | Waterhouse et al. | Jun 2020 | A1 |
20200253721 | Cuevas et al. | Aug 2020 | A1 |
20200337831 | Webb et al. | Oct 2020 | A1 |
20200337834 | Webb et al. | Oct 2020 | A1 |
20210015604 | Ma | Jan 2021 | A1 |
20210154002 | Christie et al. | May 2021 | A1 |
Number | Date | Country |
---|---|---|
2004201751 | May 2004 | AU |
1734305 | Feb 2006 | CN |
1875895 | Dec 2006 | CN |
100368846 | Feb 2008 | CN |
101322663 | Dec 2008 | CN |
102448404 | May 2012 | CN |
101341426 | Jul 2012 | CN |
203647535 | Jun 2014 | CN |
2727410 | Dec 1978 | DE |
4134320 | Apr 1992 | DE |
0165652 | Dec 1985 | EP |
0443094 | Aug 1991 | EP |
1173790 | Jan 2002 | EP |
1674049 | Jun 2006 | EP |
1548489 | Aug 2006 | EP |
2111822 | Oct 2009 | EP |
2319457 | May 2011 | EP |
2243052 | Sep 2011 | EP |
2365379 | Sep 2011 | EP |
2455799 | May 2012 | EP |
2823789 | Jan 2015 | EP |
2364457 | Aug 2015 | EP |
2993514 | Mar 2016 | EP |
2349150 | Jul 2016 | EP |
2620687 | Mar 1989 | FR |
2649605 | Jan 1991 | FR |
1276003 | Jun 1972 | GB |
2507465 | May 2014 | GB |
62-167343 | Jul 1987 | JP |
64-002644 | Jan 1989 | JP |
H01-195852 | Aug 1989 | JP |
H02-7954 | Jan 1990 | JP |
04-158859 | Jun 1992 | JP |
06-509731 | Mar 1993 | JP |
H05-65340 | Sep 1993 | JP |
06-502782 | Mar 1994 | JP |
H07-067896 | Mar 1995 | JP |
07-265340 | Oct 1995 | JP |
08-103457 | Apr 1996 | JP |
H09-502542 | Mar 1997 | JP |
11-503657 | Aug 1997 | JP |
07-178125 | Jul 1998 | JP |
2000-047145 | Feb 2000 | JP |
2002-537895 | Nov 2002 | JP |
2003-502109 | Jan 2003 | JP |
2004-510199 | Apr 2004 | JP |
2004-538034 | Dec 2004 | JP |
2005-533576 | Nov 2005 | JP |
2007-516794 | Jun 2007 | JP |
2007-523720 | Aug 2007 | JP |
2008-506710 | Mar 2008 | JP |
S59-54527 | May 2008 | JP |
2013-501598 | Jan 2013 | JP |
2015-077412 | Apr 2015 | JP |
10-0335722 | May 2002 | KR |
10-2012-0093837 | Aug 2012 | KR |
2138837 | Sep 1999 | RU |
110978 | Mar 2011 | RU |
2456968 | Jul 2012 | RU |
2457812 | Aug 2012 | RU |
2459598 | Aug 2012 | RU |
2493801 | Sep 2013 | RU |
134049 | Nov 2013 | RU |
134784 | Nov 2013 | RU |
2500368 | Dec 2013 | RU |
2511081 | Apr 2014 | RU |
2517488 | May 2014 | RU |
1380743 | Mar 1988 | SU |
201103518 | Feb 2011 | TW |
WO 8705797 | Oct 1987 | WO |
WO 9503747 | Feb 1995 | WO |
WO 9508135 | Mar 1995 | WO |
WO 9635397 | Nov 1996 | WO |
WO 9848715 | Nov 1998 | WO |
WO 00025704 | May 2000 | WO |
WO 00038594 | Jul 2000 | WO |
WO 0051682 | Sep 2000 | WO |
WO 0052516 | Sep 2000 | WO |
WO 0070388 | Nov 2000 | WO |
WO 2001010641 | Feb 2001 | WO |
WO 0115779 | Mar 2001 | WO |
WO 0117460 | Mar 2001 | WO |
WO 0119364 | Mar 2001 | WO |
WO 01082815 | Nov 2001 | WO |
WO 02076320 | Oct 2002 | WO |
WO 02102241 | Dec 2002 | WO |
WO 03020177 | Mar 2003 | WO |
WO 03022168 | Mar 2003 | WO |
WO 03061518 | Jul 2003 | WO |
WO 2004014969 | Feb 2004 | WO |
WO 2004034917 | Apr 2004 | WO |
WO 2004105588 | Dec 2004 | WO |
WO 2004113959 | Dec 2004 | WO |
WO 2005023154 | Mar 2005 | WO |
WO 2005082265 | Sep 2005 | WO |
WO 2006014738 | Feb 2006 | WO |
WO 2006020638 | Feb 2006 | WO |
WO 2006047534 | May 2006 | WO |
WO 2006060380 | Jun 2006 | WO |
WO 2006069012 | Jun 2006 | WO |
WO 2006113377 | Oct 2006 | WO |
WO 2006113411 | Oct 2006 | WO |
WO 2006113563 | Oct 2006 | WO |
WO 2006113564 | Oct 2006 | WO |
WO 2007057734 | Oct 2007 | WO |
WO 2007133384 | Nov 2007 | WO |
WO 2007142981 | Dec 2007 | WO |
WO 2008036671 | Mar 2008 | WO |
WO 2008102096 | Aug 2008 | WO |
WO 2009050511 | Apr 2009 | WO |
WO 2009122409 | Oct 2009 | WO |
WO 2009140080 | Nov 2009 | WO |
WO 2009149060 | Dec 2009 | WO |
WO 2010002215 | Jan 2010 | WO |
WO 2010059214 | May 2010 | WO |
WO 2010118469 | Oct 2010 | WO |
WO 2011020074 | Feb 2011 | WO |
WO 2011020078 | Feb 2011 | WO |
WO 2011047076 | Apr 2011 | WO |
WO 2011069059 | Jun 2011 | WO |
WO 2011088107 | Jul 2011 | WO |
WO 2012170066 | Dec 2012 | WO |
WO 2011030509 | Feb 2013 | WO |
WO 2013019871 | Feb 2013 | WO |
WO 2013082545 | Jun 2013 | WO |
WO 2013101793 | Jul 2013 | WO |
WO 2013112589 | Aug 2013 | WO |
WO 2013123265 | Aug 2013 | WO |
WO 2014054946 | Apr 2014 | WO |
WO 2014074610 | May 2014 | WO |
WO 2014158653 | Oct 2014 | WO |
WO 2014164056 | Oct 2014 | WO |
WO 2014195059 | Dec 2014 | WO |
WO 2015021323 | Feb 2015 | WO |
WO 2015069927 | May 2015 | WO |
WO 2015073718 | May 2015 | WO |
WO 2015078271 | Jun 2015 | WO |
WO 2015086611 | Jun 2015 | WO |
WO 2016081493 | May 2016 | WO |
WO 2015108156 | Mar 2017 | WO |
WO 2017062316 | Apr 2017 | WO |
WO 2017091520 | Jun 2017 | WO |
WO 2019010178 | Jan 2019 | WO |
Entry |
---|
Internet Archive Wayback Machine; Aniridia Implants; downloaded from https://web.archive.org/web/20110824062840/http://www.morcher.com/nc/produkte/aniridiaimplants.html (Archived Aug. 24, 2011; printed on Feb. 5, 2015). |
Guyton A.C., Textbook of Medical Physiology, 7th Edition, W.B. Saunders Company, Jan. 1986: Chapter 58, in 13 pages. |
Lu Xuequan, et al. “Radiation preparation and thermo-response swelling of interpenetrating polymer network hydrogel composed of PNIPAAm and PMMA”, Radiation Physics and Chemistry, vol. 57, Mar. 2000, pp. 477-480, XP002473596. |
Patel, C.K., et al. “Imaging the macula through a black occlusive intraocular lens”. Arch. Ophthalmol. Oct. 2010; 128(10):1374-1376. |
Reper-NN LTD, Instruction for Use. MOIL-Iris Iris-intaocular polymer elastic lenses, dated Aug. 2017, in 8 pages. |
Yusuf, et al., “Inability to perform posterior segment monitoring by scanning laser ophthalmoscopy or optical coherence tomography with some occlusive intraocular lenses in clinical use”, J. Cataract Refract. Surg., Mar. 2012, 38: 513-518. |
Yusuf, et al., “Occlusive IOLs for Intractable Diplopia Demonstrate a Novel Near-Infrared Window of Transmission for SLO/OCT Imaging and Clinical Assessment”. Investigative Ophthalmology & Visual Science, May 2011, 52(6): 3737-3743. |
International Search Report and Written Opinion of PCT/US2019/031189, dated Aug. 9, 2019, in 11 pages. |
Number | Date | Country | |
---|---|---|---|
20210137674 A1 | May 2021 | US |
Number | Date | Country | |
---|---|---|---|
62669295 | May 2018 | US |